← Human Trials & Peer-Reviewed Studies
Effects of topical gluco-oligosaccharide and collagen tripeptide F in the treatment of sensitive atopic skin
Plain-language guide to PMID 19496838 (2009): double-blind randomized controlled trial study of Tripeptide-29 (Collagen Tripeptide), skin sensitivity and body aches on glp-1 medicines.
Key Facts
- PMID
- 19496838
- Journal
- International journal of cosmetic science
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Berardesca E et al. (4 authors)
- DOI
- 10.1111/j.1468-2494.2009.00495.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Tripeptide-29 (Collagen Tripeptide) in the context of skin sensitivity and body aches on glp-1 medicines.
Forty female subjects (age, 30-59 years) affected by non-lesional atopic sensitive skin entered the study.
Skin sensitivity was determined by a dermatologist on the basis of medical history, stinging test, dermatological examination and a questionnaire.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, women only.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Tripeptide-29 (Collagen Tripeptide) group and the comparison group should start out alike.
As a double-blind Tripeptide-29 (Collagen Tripeptide) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Tripeptide-29 (Collagen Tripeptide) could be set against what happens without it.
The timeline in the abstract includes 4 weeks.
What Was Measured
Skin sensitivity was determined by a dermatologist on the basis of medical history, stinging test, dermatological examination and a questionnaire.
A treatment with the test products (active and placebo) was carried out for 4 weeks.
Topics PubMed links to this paper include Administration, Topical, Collagen Type I, Colony Count, Microbial, Dermatitis, Atopic, Oligosaccharides, Peptide Fragments and Staphylococcus aureus.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Tripeptide-29 (Collagen Tripeptide) in people with skin sensitivity and body aches on glp-1 medicines over 4 weeks.
The publication is from 2009 (International journal of cosmetic science), a journal based in England.
More context: the Tripeptide-29 (Collagen Tripeptide) compound page, Skin sensitivity and body aches on GLP-1 medicines research.
Our Notes on the Compound
Tripeptide-29 (Collagen Tripeptide): The collagen tripeptide Gly-Pro-Hyp, used in cosmetics and oral collagen supplements for skin hydration and elasticity.
Related Pages
- Skin sensitivity and body aches on GLP-1 medicines research
- Tripeptide-29 (Collagen Tripeptide) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.